Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations

被引:47
作者
Rogan, PK
Svojanovsky, S
Leeder, JS
机构
[1] Childrens Mercy Hosp & Clin, Lab Human Mol Genet, Kansas City, MO 64108 USA
[2] Childrens Mercy Hosp & Clin, Div Pediat Pharmacol & Med Toxicol, Kansas City, MO 64108 USA
来源
PHARMACOGENETICS | 2003年 / 13卷 / 04期
关键词
drug biotransformation; mRNA splicing; cytochrome P450; single nucleotide polymorphism; information theory; individual information;
D O I
10.1097/00008571-200304000-00005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Several mutations are known or suspected to affect mRNA splicing of CYP2C19, CYP2D6 and CYP3A5 genes; however, little experimental evidence exists to support these conclusions. The present study applies mathematical models that measure changes in information content of splice sites in these genes to demonstrate the relationship between the predicted phenotypes of these variants to the corresponding genotypes. Based on information analysis, the CYP2C19*2 variant activates a new cryptic site 40 nucleotides downstream of the natural splice site. CYP2C19*7 abolishes splicing at the exon 5 donor site. The CYP2D6*4 allele similarly inactivates splicing at the acceptor site of exon 4 and activates a new cryptic site one nucleotide downstream of the natural acceptor. CYP2D6*11 inactivates the acceptor site of exon 2. The CYP3A5*3 allele activates a new cryptic site 236 nucleotides upstream of the exon 4 natural acceptor site. CYP3A5*5 inactivates the exon 5 donor site and CYP3A5*6 strengthens a site upstream of the natural donor site, resulting in skipping of exon 7. Other previously described missense and nonsense mutations at terminal codons of exons in these genes affected splicing. CYP2D6*8 and CYPM6*14 both decrease the strength of the exon 3 donor site, producing transcripts lacking this exon. The results of information analysis are consistent with the poor metabolizer phenotypes observed in patients with these mutations, and illustrate the potential value of these mathematical models to quantitatively evaluate the functional consequences of new mutations suspected of altering mRNA splicing.
引用
收藏
页码:207 / 218
页数:12
相关论文
共 42 条
[1]   Organization of the ABCR gene:: analysis of promoter and splice junction sequences [J].
Allikmets, R ;
Wasserman, WW ;
Hutchinson, A ;
Smallwood, P ;
Nathans, J ;
Rogan, PK ;
Schneider, TD ;
Dean, M .
GENE, 1998, 215 (01) :111-122
[2]   Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population [J].
Bathum, L ;
Skjelbo, E ;
Mutabingwa, TK ;
Madsen, H ;
Horder, M ;
Brosen, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) :395-401
[3]   EXON RECOGNITION IN VERTEBRATE SPLICING [J].
BERGET, SM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (06) :2411-2414
[4]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[5]   A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE [J].
BROSEN, K ;
DEMORAIS, SMF ;
MEYER, UA ;
GOLDSTEIN, JA .
PHARMACOGENETICS, 1995, 5 (05) :312-317
[6]  
Chou FC, 2001, DRUG METAB DISPOS, V29, P1205
[7]  
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[8]   DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
STEINCKE, B ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187
[9]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[10]   Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data [J].
Gaedigk, A ;
Gotschall, RR ;
Forbes, NS ;
Simon, SD ;
Kearns, GL ;
Leeder, JS .
PHARMACOGENETICS, 1999, 9 (06) :669-682